These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 33515642)
1. Pharmacotherapy of schizophrenia: Mechanisms of antipsychotic accumulation, therapeutic action and failure. Chestnykh DA; Amato D; Kornhuber J; Müller CP Behav Brain Res; 2021 Apr; 403():113144. PubMed ID: 33515642 [TBL] [Abstract][Full Text] [Related]
2. A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Amato D; Canneva F; Cumming P; Maschauer S; Groos D; Dahlmanns JK; Grömer TW; Chiofalo L; Dahlmanns M; Zheng F; Kornhuber J; Prante O; Alzheimer C; von Hörsten S; Müller CP Mol Psychiatry; 2020 Sep; 25(9):2101-2118. PubMed ID: 30038229 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864 [TBL] [Abstract][Full Text] [Related]
5. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs? Cáceda R; Kinkead B; Nemeroff CB Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409 [TBL] [Abstract][Full Text] [Related]
6. Serotonin receptors: their key role in drugs to treat schizophrenia. Meltzer HY; Li Z; Kaneda Y; Ichikawa J Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974 [TBL] [Abstract][Full Text] [Related]
7. Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles. Tucker KR; Block ER; Levitan ES Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4485-94. PubMed ID: 26216995 [TBL] [Abstract][Full Text] [Related]
8. Atypical antipsychotics: mechanism of action. Seeman P Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706 [TBL] [Abstract][Full Text] [Related]
9. The role of serotonin receptors in the action of atypical antipsychotic drugs. Meltzer HY; Massey BW Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906 [TBL] [Abstract][Full Text] [Related]
10. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Weiner I Psychopharmacology (Berl); 2003 Sep; 169(3-4):257-97. PubMed ID: 12601500 [TBL] [Abstract][Full Text] [Related]
11. The role of dopamine D Calabrese F; Tarazi FI; Racagni G; Riva MA CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452 [TBL] [Abstract][Full Text] [Related]
12. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429 [TBL] [Abstract][Full Text] [Related]
13. Psychiatric drugs impact mitochondrial function in brain and other tissues. Chan ST; McCarthy MJ; Vawter MP Schizophr Res; 2020 Mar; 217():136-147. PubMed ID: 31744750 [TBL] [Abstract][Full Text] [Related]
14. Abnormally rapid reversal learning and reduced response to antipsychotic drugs following ovariectomy in female rats. Arad M; Weiner I Psychoneuroendocrinology; 2012 Feb; 37(2):200-12. PubMed ID: 21723667 [TBL] [Abstract][Full Text] [Related]
15. Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs. Yanagi M; Joho RH; Southcott SA; Shukla AA; Ghose S; Tamminga CA Mol Psychiatry; 2014 May; 19(5):573-9. PubMed ID: 23628987 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. Wood MD; Scott C; Clarke K; Cato KJ; Patel N; Heath J; Worby A; Gordon L; Campbell L; Riley G; Davies CH; Gribble A; Jones DN CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396 [TBL] [Abstract][Full Text] [Related]
17. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Black MD; Stevens RJ; Rogacki N; Featherstone RE; Senyah Y; Giardino O; Borowsky B; Stemmelin J; Cohen C; Pichat P; Arad M; Barak S; De Levie A; Weiner I; Griebel G; Varty GB Psychopharmacology (Berl); 2011 May; 215(1):149-63. PubMed ID: 21181124 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study. Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622 [TBL] [Abstract][Full Text] [Related]
19. Antipsychotic drug actions on gene modulation and signaling mechanisms. Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875 [TBL] [Abstract][Full Text] [Related]
20. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. Samaha AN; Seeman P; Stewart J; Rajabi H; Kapur S J Neurosci; 2007 Mar; 27(11):2979-86. PubMed ID: 17360921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]